



## Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

### Registered Office:

3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@sequent.in

Website: www.sequent.in

CIN: L99999TS1985PLC196357

February 06, 2026

To,

### **BSE Limited**

Corporate Relationship Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

### **National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East),  
Mumbai – 400 051

**Scrip code: 512529**

**Symbol: VIYASH**

### **Subject: Investor Presentation for Q3 FY 2025-26**

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter ended December 31, 2025.

This is for your information and appropriate dissemination.

You are requested to take the same on record.

Yours faithfully,

### **For Viyash Scientific Limited**

**(Formerly known as Sequent Scientific Limited)**

**Yoshita Vora**

**Company Secretary & Compliance Officer**

**Encl: A/a**

# INVESTOR PRESENTATION

---

## Q3 FY26


VIYASH SCIENTIFIC LIMITED

February 06, 2026

"We mark a significant milestone today, announcing results of the merged entity for first time. The results of Q3FY25-26 are an indication of the actions we have taken and the momentum we have built across the last few quarters, working as one team. Revenue, margins, profitability all have continued to show strong growth on the back of new product introductions, cost improvement and synergies across our business units. We have a strong balance sheet and market position and are geared up for capturing the market opportunity in the next 3-5 years. The merger is starting to generate benefits across R&D, manufacturing and front-end, all of which make us very excited for the journey ahead."

**Dr Hari Babu Bodepudi**  
Viyash Scientific Limited

# Q3FY26 Financial Snapshot



All values in ₹ Mn

## Revenues




## EBITDA<sup>1</sup>



## EBITDA margin



## Net Debt to LTM EBITDA<sup>1</sup>



All values in ₹ Mn

## Revenues




## EBITDA<sup>1</sup>



## EBITDA margin



## Net Debt to LTM EBITDA<sup>1</sup>



# Viyash Scientific: Broad based revenue growth across all businesses




All values in ₹ Mn

Revenue Distribution	Q3 FY26	Q3 FY25	YoY Gr%	Q2 FY26	QnQ Gr%	9M FY26	9M FY25	YoY Gr%
<b>Formulations</b>	<b>4,809</b>	<b>4,009</b>	<b>20%</b>	<b>4,687</b>	<b>3%</b>	<b>13,666</b>	<b>11,934</b>	<b>15%</b>
Europe	1,790	1,334	34%	1,520	18%	4,949	4,250	16%
Emerging Markets	1,630	1,366	19%	1,469	11%	4,580	3,713	23%
India	401	308	30%	362	11%	1,025	893	15%
USA	988	1,001	-1%	1,337	-26%	3,112	3,079	1%
<b>APIs</b>	<b>3,658</b>	<b>3,556</b>	<b>3%</b>	<b>3,721</b>	<b>-2%</b>	<b>11,071</b>	<b>10,098</b>	<b>10%</b>
Other Sales	85	110		62		239	257	
<b>Global Sales</b>	<b>8,552</b>	<b>7,675</b>	<b>11%</b>	<b>8,470</b>	<b>1%</b>	<b>24,976</b>	<b>22,289</b>	<b>12%</b>
One Offs <sup>#</sup>		-		-		(56)	(74)	
Adjustment* - Ind AS 29*	33	65		33		84	130	
<b>Reported Sales</b>	<b>8,584</b>	<b>7,740</b>	<b>11%</b>	<b>8,503</b>	<b>1%</b>	<b>25,004</b>	<b>22,345</b>	<b>12%</b>


\* Adjustment on account of hyperinflation in Turkey as per Ind AS 29. # Provision for customer claim on shipments in prior years

# Sustained Sales Growth with Consistent EBITDA Expansion


## Sales



## Gross Margin



## EBITDA\*



## Net Debt to LTM EBITDA




# Viyash Consolidated Financials

All values in ₹ Mn


Particulars	Q3	Q3	Grw YoY	Q2	Grw QnQ	9M	9M	Grw YoY
	FY26	FY25	%	FY26	%	FY26	FY25	%
Revenue from Operations	8,584	7,740	10.9%	8,503	1.0%	25,004	22,345	11.9%
Material Consumption	(3,909)	(3,770)		(3,785)		(11,499)	(11,054)	
<b>Gross Margin</b>	<b>4,675</b>	<b>3,971</b>	<b>17.7%</b>	<b>4,718</b>	<b>-0.9%</b>	<b>13,505</b>	<b>11,291</b>	<b>19.6%</b>
% Gross margin	54.5%	51.3%		55.5%		54.0%	50.5%	
Employee Benefit Expenses	(1,298)	(1,309)	-0.9%	(1,292)	0.4%	(3,848)	(3,683)	4.5%
Operating Expenses	(1,532)	(1,517)	0.9%	(1,588)	-3.5%	(4,690)	(4,406)	6.4%
Exchange Gain / (Loss)	8	(16)		45		57	(23)	
<b>EBITDA*</b>	<b>1,854</b>	<b>1,127</b>	<b>64.4%</b>	<b>1,883</b>	<b>-1.6%</b>	<b>5,024</b>	<b>3,179</b>	<b>58.0%</b>
% EBITDA	21.6%	14.6%		22.1%		20.1%	14.2%	
ESOP cost	(79)	(135)		(100)		(309)	(462)	
Exceptional Items	(413)	(29)		(17)		(442)	(72)	
IndAS 29 Adjustment	(5)	5		(7)		25	23	
Other Income	127	67		31		220	227	
Finance Cost	(168)	(206)		(175)		(547)	(657)	
Depreciation	(585)	(584)		(591)		(1,732)	(1,740)	
<b>Earnings Before Tax</b>	<b>731</b>	<b>245</b>	<b>198.0%</b>	<b>1,024</b>	<b>-28.6%</b>	<b>2,238</b>	<b>498</b>	<b>349.0%</b>
% Earnings before Tax	8.5%	3.2%		12.0%		9.0%	2.2%	
Taxes**	(246)	175		(295)		(655)	(19)	
<b>Earnings After Tax</b>	<b>485</b>	<b>420</b>	<b>15.5%</b>	<b>729</b>	<b>-33.5%</b>	<b>1,583</b>	<b>480</b>	<b>230.0%</b>

- + 10.9% YoY in Q3 sales with 320 bps gross margin improvement
- Finance cost reduction on account of the run-down of the debt
- Exceptional items (Total INR 413 Mn):
  - Stamp duty (INR 296 Mn)
  - Merchant banking (INR 91 Mn)
  - Other professional expenses (INR 26 Mn)
- \*\*One time MAT credit reversal impact in tax (INR 77 Mn)

# Business Update




# Formulation business – Key Pillars of success (1/2)



## Formulation business – Key Pillars of success (2/2)



R&D led portfolio expansion	Network Optimization	Business Development	New business segments
<ul style="list-style-type: none"><li>✓ Rapid new product launches giving a competitive offering to the market</li><li>✓ Identified opportunistic products to enter</li></ul>	<ul style="list-style-type: none"><li>✓ Cost optimization through process improvements and backward integration</li></ul>	<ul style="list-style-type: none"><li>✓ Focused on high end markets</li><li>✓ Cross sell of products</li></ul>	<ul style="list-style-type: none"><li>✓ Expanding lines of business through CDMO development</li></ul>



## Facility Inspections

- ✓ 3 Regulatory Audits
- ✓ 45 Customer audits



## Regulatory Approvals

- ✓ 5 APIs: (USDMF-2 ; EDQM-2; KDMF-1)



## Launches

- ✓ 5 APIs



## Products Filed

- ✓ 9 Filings – SFDA(3), EDQM (1) TGA (1), EDMF (2), WHO (1), TW (1)



## Validations Completed


- ✓ 3 APIs



## R&D Pipeline

- ✓ 17 Products

# Our vision and strategy



# Our focus areas

## Companion Animals



- Signed exclusive distribution agreement with Boehringer Ingelheim for companion animal products in India
- Building new products to deepen presence in existing markets and open new markets
- Exploring partnerships and M&A opportunities
- Build manufacturing infrastructure in India

## Farm Animals



- Geo extension: launching existing products across all core and new markets
- Filling gaps in the product portfolio to establish dominance in the markets
- Expanding into new markets

## Human Health



- Leveraging manufacturing in India for mature products
- Develop complex generics including integrated oncology portfolio

## API + CDMO



- Focus on CDMO opportunities
- Early development of complex products
- Leverage existing capacity

## “One R&D”



**250**


Membered R&D team

- Implemented for integrated product development
- Containment facility for finished product development
- Expanding team and capability to handle complex products

## There are two large strategic growth levers


### *Increasing pet ownership*

**Which is a fast growing, profitable segment and overlaps with human treatments**



### *Genericization of animal health*

**Which currently lags compared to human health**



**These trends require strong R&D and manufacturing capabilities to capitalize on these trends; Viyash poised to capture these trends**

## Market Opportunity (2/2): API patent cliff and CDMO opportunities


### Two mega trends in the API + CDMO segment

*2025-2030 patent cliff: Large number of APIs coming off patent*



*Increasing competence of India to win CDMO contracts*

- ~190+ patents coming to the market with an estimated opportunity of ~\$250bn-300bn
- This includes 60+ blockbuster products with annual sales exceeding \$1bn



***India is well poised to disproportionately benefit because of these factors:***

- Operational experience in complex manufacturing
- China +1 diversification by global innovators
- Cost advantage



## Scaled

- 200+ members (including 20+ PhDs)
- 20 fully equipped self sufficient analytical laboratories
- R&D group dedicated for support to CMO/CDMO partners



## Technically Strong


- Dedicated lab for handling cytotoxic products
- Proven capability to handle Iron complex, Inorganic products, Complex molecules
- Fully equipped dedicated Process Safety Lab



## Delivering Results

- Our efforts over the last years have now started reflecting in our strong financials

# Combined API Manufacturing Network : 10 facilities with global approvals




10 manufacturing plants in AP and Maharashtra



Plant	Unit	Capacity (KL)	Focus	US FDA	EU GMP	WHO GMP	KFDA	ANVISA	PMDA
Viyash	Unit 1	39	API / HP API	✓	✓	✓	✓		✓
	Unit 2	296	API/ HP API	✓	✓	✓		✓	
	Unit 3	80	API	✓	✓	✓	✓	✓	
	Unit 4	454	API	✓	✓	✓			
	Unit 5	137	API	✓	✓		✓	✓	
	Unit 6	487	API+Advanced Intermediates	✓		✓			✓
	Unit 7	255	Advanced Intermediates	✓					
	Unit 8	413	Advanced Intermediates	✓					
	Unit 9 (AH)	80	API		✓	✓			
Alivira Vizag	(AH)	290	API	✓		✓			

# Merger Update



## Merger process status update

- Merger has been approved by all regulatory authorities, and the merger is in effect
- **Focus on synergy realization for next 12 months**
- **The process is well on track as per estimated timelines**



Area	Key Ideation Action Items	Progress
<b>R&amp;D</b>	<ul style="list-style-type: none"> <li>• R&amp;D teams to be co-located; to work collaboratively on NPD &amp; cost improvement</li> <li>• QA &amp; Testing to be moved on-site from 3<sup>rd</sup> party location</li> </ul>	<ul style="list-style-type: none"> <li>• API R&amp;D fully integrated leading to accelerated development</li> <li>• 4 New animal health products developed/validated</li> <li>• 3 Cost improvement projects completed</li> <li>• Regulatory filing in progress</li> </ul>
<b>Manufacturing</b>	<ul style="list-style-type: none"> <li>• Utilize available low-cost capacity through the group; action plan created</li> <li>• Procurement synergies identified</li> </ul>	<ul style="list-style-type: none"> <li>• 6 Intermediates validated at Viyash sites, which were procured from external sources</li> <li>• New production block created and got EU approval; commercialization already started</li> <li>• One large volume Sequent API validated &amp; filing under progress</li> </ul>
<b>Sales</b>	<ul style="list-style-type: none"> <li>• Leverage key relationships of both companies; outreach &amp; discussion plan prepared</li> </ul>	<ul style="list-style-type: none"> <li>• Business teams working closely to identify opportunities to cross sell</li> </ul>
<b>Others</b>	<ul style="list-style-type: none"> <li>• Assess shared administrative &amp; support functions</li> </ul>	<ul style="list-style-type: none"> <li>• All support functions' integration initiated</li> </ul>

***For details, feel free to contact:***

**Yoshita Vora**

**Company Secretary**



+91 22 4111 4777



investorrelations@sequent.in

**Abhishek Singhal**

**Investor Relations Consultant**



abhishek@arunya.co.in

*Registered Office: Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India*

Websites: [www.viyash.com](http://www.viyash.com) | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: VIYASH

ISIN: INE807F01027

*Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*



Thank You